Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 5/20 | 0.41 |
| ▸ | CA2 | P00918 | 5/20 | 0.41 |
| ▸ | CA4 | P22748 | 5/20 | 0.41 |
| ▸ | CA9 | Q16790 | 5/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | DUT | P33316 | 8/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | RORC | P51449 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27203682 | 0.88 | ALDH1A1 (0.32) | ALDH1A1LMNACA1CA2CA4 | |
| SCHEMBL14528815 | 0.82 | ALDH1A1 (0.48) | ALDH1A1LMNACA1CA2CA4 | |
| SCHEMBL13663217 | 0.80 | ALDH1A1 (0.52) | ALDH1A1LMNACA1CA2CA4 | |
| SCHEMBL13660676 | 0.79 | ALDH1A1 (0.46) | ALDH1A1LMNACA1CA2CA4 | |
| SCHEMBL5097379 | 0.78 | HPGD (0.42) | CA1CA2CA9 | |
| SCHEMBL17816970 | 0.77 | MAPT (0.33) | ALDH1A1LMNACA1CA2CA4 | |
| SCHEMBL19370603 | 0.76 | ALDH1A1 (0.51) | ALDH1A1LMNACA1CA2CA4 | |
| SCHEMBL2743486 | 0.76 | MAPT (0.42) | LMNA | |
| SCHEMBL8343325 | 0.76 | ALDH1A1 (0.43) | ALDH1A1LMNACA1CA2CA4 | |
| SCHEMBL27203701 | 0.75 | BCL6 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10577396-B2 | Tolan compound | OSAKA UNIVERSITY (JP) | 2020-03-03 | — | — | US | disclosed |
| WO-2017047807-A1 | TOLAN COMPOUND | 国立大学法人大阪大学 | 2017-03-23 | — | — | WO | disclosed |
| US-5977296-A | MONOMERS WITH ALIPHATIC CYCLIC STRUCTURE IN THE BACKBONE; FOR INCREASED CONFORMATION RESTRICTION LEADING TO INCREASED BINDING AFFINITY AND SPECIFICITY; FOR DETECTING POINT MUTATIONS, FOR SUPPRESSING WILD TYPE GENES IN AMPLIFICATION | NIELSEN, PETER E. (DK) | 1999-11-02 | — | — | US | disclosed |
| WO-1996020212-A2 | PEPTIDE NUCLEIC ACID INCORPORATING A CHIRAL BACKBONE | BUCHARDT, DORTE (DK) | 1996-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10577396-B2 | Tolan compound | TAP1, GRN, TSG101 | ALDH1A1 1789/4885LMNA 668/4885CA1 4682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.